SCN1A rs3812696: Anti-Seizure Drug Response & Dosing
The rs3812696 single-nucleotide polymorphism is a common non-coding variant located in the SCN1A gene, historically designated in medical literature as IVS5N+5G>A or c.603-91G>A. It impacts alternative splicing of voltage-gated sodium channels in the central nervous system and has been evaluated for its influence on dosage requirements and clinical efficacy of sodium channel-blocking anti-seizure medications. While early studies linked the variant to differences in maximum therapeutic doses for drugs such as carbamazepine and phenytoin, overall clinical evidence remains limited and mixed across diverse populations.
What each genotype means
Higher dose requirement
Research suggests that individuals with this genotype may require higher maximum doses of anti-seizure medications like phenytoin and carbamazepine to achieve clinical control. This association is based on population-level observations of drug dosing trends. Please discuss your medication dosing and clinical response with your neurologist or pharmacist.
This genotype is common in many populations, though exact frequencies vary significantly by ancestry.
Intermediate dose requirement
Individuals with this genotype often show intermediate trends in the maximum doses of phenytoin and carbamazepine required for seizure management compared to other genotypes. These findings reflect statistical associations in clinical populations rather than individual predictions. Always consult your healthcare provider regarding your specific treatment plan and medication adjustments.
This is a frequently observed genotype across diverse global populations.
Lower dose requirement
Studies indicate that individuals with this genotype may be associated with lower maximum dose requirements for medications such as phenytoin and carbamazepine. This observation is based on statistical trends in epilepsy patients and does not guarantee a specific clinical outcome. Please work closely with your clinician to determine the appropriate dosage for your individual needs.
This genotype is found at varying frequencies globally, representing one of the common variations at this site.
Genomic Location and Biological Mechanism
The single-nucleotide polymorphism rs3812696 is situated in an intronic region of the SCN1A gene on chromosome 2. SCN1A provides instructions for building the alpha subunit of the Nav1.1 voltage-gated sodium channel, an essential protein complex responsible for the generation and propagation of electrical action potentials in neuronal cell membranes. The rs3812696 variant involves a substitution of guanine (G) to adenine (A) near an alternative splice site between exons 5N (neonatal) and 5A (adult). Molecular studies demonstrate that the presence of the A allele alters the ratio of these alternative transcripts, altering the expression pattern of the channel isoforms in human brain tissue. Because anti-epileptic medications such as phenytoin and carbamazepine achieve their therapeutic effect by directly binding and blocking these voltage-gated sodium channels, changes in alternative splicing could theoretically alter channel pharmacology or drug sensitivity.
Pharmacogenomic Associations and Clinical Evidence
Initial candidate-gene studies reported that individuals carrying the A allele required significantly higher maintenance and maximum doses of carbamazepine and phenytoin to achieve seizure control compared to individuals homozygous for the ancestral G allele. This biological plausibility spurred interest in utilizing rs3812696 as a pharmacogenomic marker for dosing optimization. However, subsequent replication attempts and meta-analyses across larger global cohorts have generated conflicting outcomes. Multiple investigations observed no statistically significant association between rs3812696 genotype and drug resistance, clinical efficacy, or standard maintenance dosing. Consequently, major pharmacogenomics consortia, including the Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB, classify the clinical evidence for rs3812696 as limited or preliminary, meaning it does not currently meet the standard required for actionable clinical dosing guidelines.
Population Distribution and Ancestry Differences
The alleles of rs3812696 are common across the world, but their frequencies exhibit notable variation depending on biogeographical ancestry. According to public population genomic datasets like gnomAD and dbSNP, the minor A allele occurs at an estimated frequency of approximately 40% in individuals of European ancestry and roughly 45% in East Asian populations. In contrast, the A allele is considerably less frequent among populations of African ancestry, where it typically hovers around 15%. Because baseline allele frequencies vary widely and the strength of the reported pharmacogenomic association varies between study cohorts, researchers emphasize that statistical associations observed in one ancestral group cannot be assumed to translate across different genetic backgrounds or clinical settings.
Interpreting Genetic Data and Clinical Reality
It is critical to understand the distinction between statistical association and clinical actionability. Carrying one or two copies of the rs3812696 A allele does not mean an individual is resistant to anti-seizure therapies, nor does it guarantee that a higher dose will be necessary. Anti-epileptic drug metabolism and clinical response depend on a complex combination of clinical variables, including hepatic enzymes such as CYP2C9 and CYP3A4, patient age, renal clearance, serum drug concentration monitoring, and concurrent medications. Direct-to-consumer genetic findings for rs3812696 should never be used independently to initiate, discontinue, or alter any medication regimen. Any questions regarding anti-seizure medication selection or dose titration must always be evaluated in consultation with a qualified neurologist or clinical pharmacist.
How common is this variant?
The minor A allele occurs at a frequency of approximately 0.40 in European ancestries and 0.45 in East Asian populations, while it is observed at a lower frequency of about 0.15 in African ancestries.
Frequently asked questions
What is SCN1A rs3812696?
SCN1A rs3812696 is a common single-nucleotide polymorphism located in an intronic region of the SCN1A gene, which codes for a brain sodium channel subunit. It has been studied extensively for its role in altering mRNA splicing and its potential impact on how people respond to certain anti-epileptic drugs.
Does carrying the AA genotype mean my anti-seizure medication won't work?
No. Carrying the AA genotype does not indicate treatment failure or drug resistance. While some early studies associated the A allele with higher maximum doses of medications like carbamazepine or phenytoin, the overall scientific evidence is conflicting and cannot predict individual response.
Can rs3812696 testing be used to choose my epilepsy medication dose?
No, professional bodies such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) do not currently recommend modifying drug dosages based on rs3812696. Anti-seizure medications are dosed based on clinical response, tolerability, and therapeutic drug monitoring.
Is rs3812696 linked to Dravet syndrome?
While rare, severe loss-of-function mutations in the SCN1A gene are the primary cause of Dravet syndrome, rs3812696 is a common variant present in tens of millions of healthy individuals and does not cause Dravet syndrome.
What should I do if my genetic test shows I carry the A allele?
You should not alter your prescription or adjust your medication schedule in any way. Always share your complete genetic testing results with your prescribing physician or a clinical pharmacist to discuss how they fit into your overall medical care.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs3812696?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SCN1A
Variant assessed for responsiveness to sodium-channel-blocking antiepileptic drugs.
Intronic regulatory variant in SCN1A associated via clinical PGx studies with altered therapeutic dosing requirements and pharmacoresistance to carbamazepine and phenytoin.
A variant in the SCN1A gene that may influence the effective dosage and side-effect profile of phenytoin and other anti-epileptic drugs.